Chirantan Chatterjee - Google Scholar

Cited by

	All	Since 2015
Citations	407	328
h-index	11	10
i10-index	13	12

20082009201020112012201320142015201620172018201920201 4 5 5 12 13 33 29 45 43 65 77 62

Co-authors

Lee BranstetterProfessor of Public Policy and Economics, Carnegie Mellon UniversityVerified email at cmu.edu
Matthew J. HigginsDavid Eccles Professor of Entrepreneurship & Strategy, David Eccles School of Business, UniversityVerified email at eccles.utah.edu
Arzi AdbiNational University of SingaporeVerified email at nus.edu.sg
Ashish AroraFuqua School of BusinessVerified email at duke.edu
Enrico PenningsProfessor of Applied Industrial Organization at Erasmus School of EconomicsVerified email at ese.eur.nl
Matej DrevGeorgia Institute of TechnologyVerified email at pubpolicy.gatech.edu
Jasjit SinghProfessor of Strategy and Paul Dubrule Chair in Sustainable Development, INSEADVerified email at insead.edu
Zoe KiniasAssociate Professor and Area Chair of Organizational Behavior, INSEADVerified email at insead.edu
Neeraj SoodSol Price School of Public Policy, Schaeffer Center, USCVerified email at usc.edu
Kamal SaggiVanderbilt UniversityVerified email at vanderbilt.edu
Anant MishraAssociate Professor at University of MinnesotaVerified email at umn.edu
Prof. Viswanath PingaliEconomics area, Indian Institute of ManagementVerified email at iimahd.ernet.in
D. Daniel SokolLaw, University of Florida Levin College of LawVerified email at law.ufl.edu
Anand NandkumarIndian School of BusinessVerified email at isb.edu

Chirantan Chatterjee

ICICI Bank Chair & Faculty Member (IIMA), Visiting Fellow, Hoover Institution

Verified email at iima.ac.in - Homepage

Economics of Technological Change/Pharmaceutical Economics


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry L Branstetter, C Chatterjee, MJ Higgins The RAND Journal of Economics 47 (4), 857-890, 2016	85	2016
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry L Branstetter, C Chatterjee, MJ Higgins The RAND Journal of Economics 47 (4), 857-890, 2016	85	2016
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry L Branstetter, C Chatterjee, MJ Higgins The RAND Journal of Economics 47 (4), 857-890, 2016	85	2016
Does environmental regulation indirectly induce upstream innovation? New evidence from India P Chakraborty, C Chatterjee Research Policy 46 (5), 939-955, 2017	45	2017
Strong medicine: patent reform and the emergence of a research-driven pharmaceutical industry in India A Arora, L Branstetter, C Chatterjee NBER Conference on Location of Biopharmaceutical Activity, Boston, MA, 7-8, 2008	39	2008
Strong medicine: Patent reform and the emergence of a research-driven pharmaceutical industry in India A Arora, L Branstetter, C Chatterjee NBER Conference on Location of Biopharmaceutical Activity, Boston, MA, 7-8, 2008	39	2008
Ethical issues in health care sector in India C Chatterjee, V Srinivasan IIMB Management Review 25 (1), 49-62, 2013	31	2013
Starving (or fattening) the golden goose?: Generic entry and the incentives for early-stage pharmaceutical innovation L Branstetter, C Chatterjee, MJ Higgins National Bureau of Economic Research Working Paper Series, 2014	29	2014
Starving (or fattening) the golden goose?: generic entry and the incentives for early-stage pharmaceutical innovation L Branstetter, C Chatterjee, MJ Higgins National Bureau of Economic Research, 2014	29	2014
The case for dynamic pricing A Farahmand, C Chatterjee Hospitality Upgrade 5 (1), 154-155, 2008	17	2008
The consumer welfare implications of governmental policies and firm strategy in markets for medicines C Chatterjee, K Kubo, V Pingali Journal of Health Economics 44, 255-273, 2015	16	2015
The consumer welfare implications of governmental policies and firm strategy in markets for medicines C Chatterjee, K Kubo, V Pingali Journal of Health Economics 44, 255-273, 2015	16	2015
Strong medicine? Patent reform and the transformation of the Indian pharmaceutical industry A Arora, L Branstetter, C Chatterjee, K Saggi mimeo, 2009	15	2009
Gender and its rising role in modern Indian innovation and entrepreneurship C Chatterjee, S Ramu IIMB Management Review 30 (1), 62-72, 2018	14	2018
Mitigating regulatory impact: the case of partial price controls on metformin in India A Bhaskarabhatla, C Chatterjee, P Anurag, E Pennings Health policy and planning 32 (2), 194-204, 2017	14	2017
Price Control and Access to Drugs: The Case of India’s Malaria Market D Mohapatra, C Chatterjee Working Paper. Cornell University, 2015	13	2015
Hit where it hurts: cartel policing using targeted sales and supply embargoes A Bhaskarabhatla, C Chatterjee, B Karreman The Journal of Law and Economics 59 (4), 805-846, 2016	11	2016
Innovation and internationalisation in the Indian software industry: Wipro–Going forward: Interview with Rishad Premji, Chief Strategy Officer, Wipro Limited C Chatterjee IIMB management Review 26 (1), 59-64, 2014	10	2014
Government health insurance and spatial peer effects: New evidence from India C Chatterjee, R Joshi, N Sood, P Boregowda Social Science & Medicine 196, 131-141, 2018	7	2018
The role of physicians in prescribing irrational fixed-dose combination medicines in India A Bhaskarabhatla, C Chatterjee Social science & medicine 174, 179-187, 2017	7	2017

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Upload PDF

Follow this author

Cited by

Co-authors